Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D09DIB
|
|||
Former ID |
DIB004058
|
|||
Drug Name |
RG-4929
|
|||
Synonyms |
R-4929; RO-5093151; 11-beta HSD inhibitor (type 2 diabetes), Roche; 11-beta hydroxysteroid dehydrogenase inhibitor (type 2 diabetes), Roche
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Metabolic disorder [ICD-11: 5C50-5D2Z; ICD-10: E70-E90; ICD-9: 270-279] | Phase 2 | [1] | |
Company |
F Hoffmann-La Roche Ltd
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H27ClN2O2
|
|||
Canonical SMILES |
C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4.Cl
|
|||
InChI |
1S/C23H26N2O2.ClH/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18;/h1-10,20H,11-17H2,(H,24,26,27);1H
|
|||
InChIKey |
XSOOSXRNMDUWEM-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 5633-14-7
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) | Target Info | Inhibitor | [2] |
KEGG Pathway | Steroid hormone biosynthesis | |||
Metabolism of xenobiotics by cytochrome P450 | ||||
Metabolic pathways | ||||
Chemical carcinogenesis | ||||
NetPath Pathway | IL1 Signaling Pathway | |||
FSH Signaling Pathway | ||||
Pathwhiz Pathway | Steroidogenesis | |||
Reactome | Glucocorticoid biosynthesis | |||
WikiPathways | Prostaglandin Synthesis and Regulation | |||
Metabolism of steroid hormones and vitamin D | ||||
Glucocorticoid & Mineralcorticoid Metabolism |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01493271) A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma. U.S. National Institutes of Health. | |||
REF 2 | New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.